PharmaTimes

DECEMBER 18, 2023

Scientists recruited 49 volunteers with mild cognitive impairment (MCI) and 45 healthy adults aged 55 years and older who had previously undergone an MRI to measure changes in brain structure and two positron emission tomography (PET) scans of their brains at Johns Hopkins between 2009 and 2022.

Transportation 84

Transportation Medicine Recruitment Patients 84

World of DTC Marketing

FEBRUARY 25, 2021

Researchers presented the fact-box idea to the FDA in 2009, but the agency decided not to create the boxes, determining “that the inclusion of such quantitative information in a standardized format cannot be readily applied to many drugs.” It other words it would easily communicate drug side effects to patients.

Side effects 173

Side effects Prescription FDA Medical 173

World of DTC Marketing

MAY 26, 2021

Humira’s net price—which subtracts discounts and rebates—increased by 110% between 2009 and 2018, from $16,663 per year to $35,041 per year. billion in “Humira Research & Development” expenditures between 2009 and 2018—approximately 4.2% of the company’s Humira worldwide net revenue over that period. The post 470% price increases.

Competition 180

Competition Marketing Government Patients 180

PM360

AUGUST 17, 2022

The Trailblazer Awards were established in 2009 to recognize and honor outstanding companies, marketers, marketing teams, brand managers, and initiatives that have demonstrated innovation and achieved incredible results in the life sciences. The finalists are in for PM360’s 14 th annual Trailblazer Awards.

Education 105

Education Marketing Pharma Media 105

Pharmaceutical Technology

JUNE 23, 2022

It was discovered by Incyte and licensed to Novartis in 2009. A kinase inhibitor, Tabrecta acts on MET. The latest development comes after the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) provided a positive opinion in April this year.

Medicine 105

Medicine Leads Patients Pharmaceutical 105

Pharmacy Times

JULY 18, 2022

Influenza viruses typically circulate in the Northern Hemisphere during the winter and spring, but they occasionally can circulate more during the summer months, as did the 2009 H1N1 pandemic strain.

26

26

European Pharmaceutical Review

FEBRUARY 23, 2023

Monocyte-activation test (MAT), added in 2009, provided an in-vitro alternative to the RPT. Therefore, a test covering all types of pyrogens is required to confirm the absence of non-endotoxin pyrogens. General chapter 2.6.30. It can detect both endotoxin and non-endotoxin pyrogens.

Consulting 98

Consulting Pharmaceutical 98

Pharma Marketing Network

JULY 17, 2023

Along the way, he has worked for the likes of Havas, Cushman & Wakefield and began a deep dive into the healthcare arena in 2009 when he joined Inventiv Health as Head of Digital & innovation. He joined Ogilvy in 2014, as the Chief Digital Officer for Ogilvy CommonHealth, the specialist health care agency within the Ogilvy Group.

Consulting 52

Consulting Education Networking Healthcare 52

World of DTC Marketing

JANUARY 10, 2022

This study included 63 of 355 new therapeutic drugs and biologic agents approved by the US Food and Drug Administration between 2009 and 2018. A study in 2020 estimated that the median cost of getting a new drug into the market was $985 million, and the average price was $1.3

Food and Drug Administration 213

Food and Drug Administration Pharma Marketing Food 213

European Pharmaceutical Review

JANUARY 25, 2024

“Proposal for a Directive of the European Parliament and of the Council on the Union code relating to medicinal products for human use, and repealing Directive 2001/83/EC and Directive 2009/35/EC.” Article 63 EMA (29 January 2020). Key principles for the use of electronic product information for EU medicines” Breinstrup T.

Healthcare 98

Healthcare Healthcare Safety Electronics 98

PM360

AUGUST 24, 2023

Established in 2009, the Trailblazer Awards recognize and honor outstanding companies, marketers, marketing teams, brand managers, and initiatives that have demonstrated innovation and achieved incredible results in the life sciences. The finalists are in for PM360’s 15 th annual Trailblazer Awards.

Education 98

Education Marketing Media Patients 98

Med Device Careers

JULY 19, 2021

Since founding PrepMD in 2009, Matt has overseen an organization that has graduated over 500 qualified medical device candidates into the workforce and has expanded business operations to include contract staffing and direct placement services as well as a rapidly expanding cardiac device remote monitoring division.

Medical 52

Medical Training Recruitment Healthcare 52

Clarivate

OCTOBER 31, 2023

It shows an acceleration in published research output, which increased five-fold between 2009 and 2021, well outpacing the U.S. Our latest ISI report, China’s research landscape , draws on Web of Science data to reveal the trajectory and dynamics of China’s research landscape. Our analysis suggests this trajectory is likely to continue.

Engineering 75

Engineering Leads Networking Electronics 75

pharmaphorum

JANUARY 24, 2023

Over the last 25 years, the headcount in the medicines manufacturing sector has fallen by 7,000 and since 2009 production volumes have fallen by nearly a third (29%), suggesting “faltering attractiveness” of the UK for manufacturing. Established trends are unfortunately firmly in the wrong direction.

Manufacturing 108

Manufacturing Medicine Government Pharmaceutical manufacturing 108

Pharmaceutical Technology

SEPTEMBER 22, 2022

Since 2009, Meiji has marketed tebipenem HBr in Japan. Under the deal, GSK will obtain an exclusive licence for the development and marketing of tebipenem pivoxil HBr in all countries. This licence will exclude Japan and certain Asian countries, which will be retained by Spero partner Meiji Seika Pharma.

Food and Drug Administration 59

Food and Drug Administration Marketing FDA Media 59

pharmaphorum

OCTOBER 19, 2022

Alongside his work as a recognised author, speaker, moderator and industry advisor, he founded the industry-leading publication pharmaphorum in 2009. Dr Paul Tunnah, chief content officer and managing director UK, Healthware (moderator). The post How the Digital Patient Experience is Shaping the Future of Pharma appeared first on.

Patients 94

Patients Pharma Management Sales technology 94

pharmaphorum

JANUARY 4, 2023

The drug was originally developed by CV Therapeutics – bought by Gilead in 2009 – and first launched in the US in 2008. According to IQVIA figures, US sales of Lexiscan were approximately $650 million for the 12 months that ended 31 March 2022, making it one of Astellas’ top products. It is sold as Rapiscan in Europe by GE Healthcare.

Pharmacology 59

Pharmacology Marketing Pharma Competition 59

pharmaphorum

NOVEMBER 6, 2022

3) Biolojic Design : Founded in 2009, the Israeli company uses a structure-based approach, where their model is trained on millions of Antibody-Antigen pairs in order to identify a template antibody against the desired target from existing human antibodies. They have five programs in internal pipeline and partnered programs.

Biopharma 109

Biopharma Pharma Training Leads 109

pharmaphorum

JANUARY 3, 2023

ReNeuron was founded in the late 1990s and floated in 2000, but saw slow progress with its stem cell therapies, with approval to start clinical testing arriving in 2009 after the UK cleared a trial of a stroke therapy. Isted joined ReNeuron as chief financial officer in 2021, before stepping up to the top job for just a few months.

Biopharma 59

Biopharma Pharma Leads Management 59

World of DTC Marketing

DECEMBER 18, 2020

healthcare system saved almost $2 trillion from 2009 to 2019 in healthcare costs due to generic drugs. When both brand and generic versions of the prescribed medication were available, the generic was chosen 97 percent of the time, resulting in significant patient savings.

Pharma 155

Pharma Prescription Media Healthcare 155

pharmaphorum

SEPTEMBER 26, 2022

Lexiscan was originally developed by CV Therapeutics, which licensed rights to the drug to Astellas shortly before the Japanese pharma launched a hostile bid for the company – thwarted when it was acquired by Gilead in 2009. The post Astellas facing generics to big-selling Lexiscan product in US appeared first on.

Pharmacology 52

Pharmacology FDA Marketing Pharma 52

European Pharmaceutical Review

APRIL 10, 2023

A 2009 study by Eigner et al. On the other hand, the Shimadzu MS showed a high-confidence identification for 639 isolates (88.8 All the high-confidence MS identifications were accurate at the genus level. on 1116 routine isolates representing the main bacterial groups encountered in the clinical microbiology laboratory, showed 95.2

Media 127

Media Healthcare Healthcare Pharmaceutical 127

Clarivate

JUNE 21, 2024

They differ from traditional literature reviews in that they typically adhere to strict methodological guidelines such as those issued by the Cochrane Collaboration (Cochrane, 2019) and the Centre for Reviews & Dissemination (Centre for Reviews and Discussion, 2009). Centre for Reviews and Discussion, 2009. Cochrane Crowd [Online].

Training 81

Training Government Medical science Ethics 81

Pharmaceutical Technology

APRIL 12, 2023

Since the inception of the ACA, changes in cancer screening among privately insured individuals show an overall increase in colorectal cancer screening tests.

Insurance 52

Insurance Leads Medical 52

Pharmaceutical Technology

JULY 29, 2022

Abilify (aripiprazole) , marketed by Bristol Myers Squibb and Otsuka Pharmaceuticals, was approved in 2009 for irritability treatment in six to 17-year-old children with ASD. Generic versions of both drugs are now available.

Side effects 105

Side effects Medical Pharmaceutical Management 105

pharmaphorum

JUNE 28, 2022

Ceftobiprole was turned down by the FDA in 2009 for ABSSSI, when the drug was partnered with Johnson & Johnson’s Janssen Cilag unit. If it gets a green light, it will be the first antibiotic in the beta-lactam class to or the treatment of SAB S.

Side effects 52

Side effects FDA Marketing Government 52

pharmaphorum

OCTOBER 28, 2022

Alongside his work as a recognised author, speaker, moderator and industry advisor, he founded the industry-leading publication pharmaphorum in 2009. Dr Paul Tunnah, chief content officer and managing director UK, Healthware (moderator).

Medicine 114

Medicine Management Marketing Leads 114

pharmaphorum

SEPTEMBER 27, 2022

The suit claimed that Biogen paid millions of dollars to doctors in the form of speaker honoraria, training fees, consulting fees, and meals to induce them to prescribe the MS drugs Avonex (interferon-beta-1a), Tysabri (natalizumab), and Tecfidera (dimethyl fumarate) between 2009 and 2014.

Government 45

Government Doctors Consulting Training 45

World of DTC Marketing

FEBRUARY 4, 2021

As early as 2009, Merck knew of more than 200 reports of depression, including suicidal thoughts, in men taking Propecia, according to an internal “risk management” assessment from that year. Annual U.S. prescriptions of finasteride, as the drug is known, for hair loss increased to over 2.4

Pharma 180

Pharma Food and Drug Administration Side effects Safety 180

Nixon Gwilt Law

JUNE 10, 2024

Multi-Million-Dollar Penalties and the Evolution of the HBNR The HBNR was first implemented by the FTC [CN2] in 2009 to advance the use of health information technology while strengthening privacy and security protections for health information not covered by HIPAA. Beginning in 2021, this long-held position began to change.

Electronics 52

Electronics Healthcare Healthcare Medical 52

Nixon Gwilt Law

JUNE 10, 2024

Multi-Million-Dollar Penalties and the Evolution of the HBNR The HBNR was first implemented by the FTC [CN2] in 2009 to advance the use of health information technology while strengthening privacy and security protections for health information not covered by HIPAA. Beginning in 2021, this long-held position began to change.

Electronics 52

Electronics Healthcare Healthcare Medical 52

pharmaphorum

AUGUST 24, 2022

A federal judge has ruled that a jury trial will be needed to resolve allegations that Indivior attempted to preserve a monopoly by switching to a sublingual film formulation of Suboxone (buprenorphine/naloxone) in 2009 from an older pill version of the product.

Competition 52

Competition Marketing Healthcare Healthcare 52

pharmaphorum

OCTOBER 13, 2022

Mr. Baxter joined VBI in September of 2009. Stern School of Business at New York University and a Bachelor of Sciences in Supply Chain Management from the Martin J. Whitman School of Management at Syracuse University. Jeff Baxter – President and CEO, VBI Vaccines.

Management 52

Management Pharma Consulting Leads 52

Salesforce

AUGUST 2, 2022

share-price gain during the 2007-2009 downturn, while the broader stock market declined by 35%, according to an AARP study. share-price gain during the 2007-2009 downturn, while the broader stock market declined by 35%. Inclusive companies (with a diverse workforce across age, gender, race, sexuality, and ability), posted a 14.4%

Training 98

Training Recruitment Marketing Management 98

European Pharmaceutical Review

FEBRUARY 22, 2023

Characterization of natural wax esters by MALDI-TOF mass spectrometry, J Mass Spectrom , 2009, 44, 101–110. An overview, J Incl Phenom Macrocycl Chem , 2009, 65, 237-248. Vrkoslav V, Míková R, Cvačka J. Tran A, Monreal IA, et al. 2021, 32, 289–300. Norkus E, Metal ion complexes with native cyclodextrins. Chen Y, Zou Z, Dai X, et al.

Food 98

Food Electronics Pharmaceutical Doctors 98

MedReps

OCTOBER 25, 2022

According to a study done back in 2009 , physicians had some interesting things to say about the medical sales representatives they encountered: 87% of those interviewed wanted more clinical studies and fewer glossy brochures. This will help them realize just how useful and well-tested the products are. Why Does Evidence-Based Selling Work?

Medical sales 86

Medical sales Sales Medical Physicians 86

Clarivate

NOVEMBER 10, 2022

The evidence standards that a COA must meet to support key clinical trial endpoints have become increasingly stringent in recent decades, following the introduction of the United States Food and Drug Administration (FDA) Patient Reported Outcomes (PRO) draft guidance in 2006, followed by the full guidance in 2009.

Patients 52

Patients Food and Drug Administration FDA Safety 52